IDT Biologika

Request more information from IDT Biologika

Yes, Please subscribe me to your weekly eNewsletters and Alerts

Yes, I wish to receive special promotions and offers from your affiliates.

Yes, I would like to learn more about IDT Biologika. Please contact me by Phone or Email

By completing this form, you are accepting our Terms of Use and Privacy Policy.

With Passion, We Bring Pharmaceutical Solutions to Life

IDT Biologika is a global biopharmaceutical contract development and manufacturing organization (CDMO) specializing in vaccines, gene and immune therapeutics, and the fill-finish of other sterile injectables. With decades of experience across various vaccine platforms, we integrate cutting-edge innovations in advanced therapies and our expertise in fill-finish to provide tailored solutions that support our customers in advancing their products.

Our end-to-end services include process development, drug substance manufacturing, sterile dosage filling, labeling, packaging and quality control. All analytical services are performed in-house. From early-stage development to clinical and commercial manufacturing, we ensure seamless integration at every step, delivering flexibility, regulatory compliance, and the highest quality standards. Our commitment to operational excellence is reflected in our best-in-class process and GMP manufacturing, meeting FDA, EMA and ANVISA standards.

Driven by passion, innovation, and a commitment to excellence, we strive to make a meaningful impact on global healthcare by helping our customers bring their products to market.

Vision & Mission

Our Vision

The trusted partner in shaping a healthier world

Our vision reflects our commitment as a CDMO to fostering strong, reliable partnerships. At IDT Biologika, we work hand in hand with our customers to create innovative solutions that advance global health. Our dedication to trust and collaboration ensures that together, we can build a healthier world for all.

Our mission serves as a clear roadmap, guiding us through each step to ensure we stay focused and aligned with our long-term goals.

Our Mission

With passion we bring pharmaceutical solutions to life

Our mission emphasizes that we are deeply committed and enthusiastic about delivering impactful pharmaceutical solutions to our customers. Our passion drives us toward innovation, quality, and excellence, and the desire to make the difference. This statement underscores the importance of both excellence and passion in supporting our customers in delivering solutions that improve patient outcomes and contribute to global health advancements.

Environmental, Social, Governance

Our dedication to ESG principles are integral to everything we do and guide our decision making, fostering trust and long-term value value creation. This commitment has been recognized with the Ecovadis Gold medal in 2024. IDT Biologika is also member of UN Global Compact.

US Sales Office Contact:

Lifeng He: (951) 719-9718

Posters

Shortening the Timeline from Customer into Clinics: Development of a Downstream Processing Platform for Adeno-associated virus (AAV)

IDT has developed a purification platform for AAV based on sophisticated experimental data and a multi-criteria decision matrix.

Released By IDT Biologika

Posters

Pandemic preparedness: Overcoming Challenges in a 2000 Liter Scale Up for Adenovirus-based Vaccine Manufacturing

The COVID-19 pandemic demonstrated that the mass production of vaccines is crucial for our healthcare system. In order to provide large quantities in a short time span, high capacity technology is inevitable2,3. IDT Biologika has established a pandemic preparedness concept that demonstrates our readiness for viral vector vaccine mass production. In this manner, we have […]

Released By IDT Biologika

Posters

Continuously Improving Quality and Efficiency of AAV Manufacturing

The field of AAV-based gene therapies is rapidly evolving. This applies to aspects such as manufacturing, analytics and regulations which are core competencies of IDT Biologika, a full-service CDMO specialized in virus-based therapies and vaccines. In the following, we present insights into our cross-serotype, robust high-yield AAV manufacturing platform. The platform was established with the […]

Released By IDT Biologika

Posters

Adaptation of an Adherent hck (MDCK) Cell Line to a Serum-Free Suspension RCB for MCB Production

An engineered Madin-Darby canine kidney (MDCK) cell line that is more suitable for human influenza virus isolation and propagation was developed by Takada et al. By altering the expression levels of α-2, 6- sialoglycans and α-2, 3-sialoglycans of the host cell. However, the adherent nature of this humanized MDCK (hCK) cell line limits the scalability […]

Released By IDT Biologika

White Papers / Tech Papers

Preparing for Disease X – Effective Vaccine Development in the Face of a Future Pandemic

CDMOs and other critical vaccine manufacturers play a major part in the prevention of future pandemics, due to their essential role in the development and implementation of novel vaccine manufacturing technologies. Currently, organizations such as the “Coalition for Epidemic Preparedness Innovations” (CEPI)1 are establishing strategies to accelerate the development of potential vaccine candidates. To keep […]

Released By IDT Biologika

White Papers / Tech Papers

GMP-Validated Adventitious Virus Testing By Next Generation Sequencing

Safety, quality, and efficacy of biologics are the basis for approving and authorizing through state regulatory bodies. Safety is ensured among other activities by quality controls during the manufacturing process. This also includes testing for unwanted agents which pose a threat to human health. This safety control step is called Adventitious Agent Testing. Here, we […]

Released By IDT Biologika

White Papers / Tech Papers

Lyophilization Vs. Liquid Formulation: Why Lyo Offers Advantages For Drug Manufacturers

As biologics such as vaccines, gene therapy and therapeutic proteins continue to advance to commercial viability, their complexities when compared to small molecules will necessitate new and novel approaches. These drugs are susceptible to conformational changes, protein aggregation, and other issues resulting from temperature changes, freeze-thaw cycles, the introduction of certain excipients and buffers, and […]

Released By IDT Biologika

IDT Biologika‘s Analytical and Quality Control Strategy for Your Therapies

A strong risk and quality control strategy is essential to ensuring the safety, efficacy, and consistency of pharmaceutical manufacturing. By identifying and addressing potential risks early, we prevent costly errors and delays, ensuring smooth and efficient manufacturing of your products. IDT Biologika is a leading cell & gene therapy CDMO with an exceptional track record […]

Released By IDT Biologika

Synergies Between IDT Biologika‘s Vaccine Expertise on the Development and Manufacturing of Cell and Gene Products

What defines a leading Vaccine CDMO in the Cell and Gene Therapy business? The production of viral vectors and the manufacturing of cell and gene therapeutics are closely interlinked processes that offer significant synergies. Leveraging these synergies can enhance efficiency, reduce costs, and improve product safety – ultimately delivering multiple benefits to customers. Synergies in […]

Released By IDT Biologika

Literature / Brochures

End-to-End Services in Contract Manufacturing

Process & Analytical Development • Drug Substance • Aseptic Fill-Finish • Packaging

Released By IDT Biologika

White Papers / Tech Papers

Overcoming Challenges in AAV and LV Viral Vector Manufacturing

How to design and launch a successful Clinical Trial Manufacturing.

Released By IDT Biologika

News Releases

SK bioscience Completes Acquisition of Controlling Stake in IDT Biologika

SK bioscience, a global vaccine and biotech company with its headquarters in South Korea, today announced the successful completion of its acquisition of a controlling stake in IDT Biologika, a leading CDMO providing end-to-end services in the development and manufacture of viral vaccines, cell and gene therapy products and aseptic fill-finish of other biologics and […]

Released By IDT Biologika